| NCT ID | NCT07231315 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The George Institute |
| Condition | Intracerebral Hemorrhage |
| Study Type | OBSERVATIONAL |
| Enrollment | 163 participants |
| Start Date | 2026-09-18 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 163 participants in total. It began in 2026-09-18 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
As an investigator-initiated and conducted, multi-centre, open-label, single-arm prospective observational trial, INTERACT4 Expansion aims to evaluate the feasibility of setting up and conducting a trial that uses a point-of-care GFAP test to identify ICH in patients presenting with acute stroke-like symptoms in the pre-hospital setting.
Eligibility Criteria
Inclusion Criteria: 1. Adults (age ≥18 years); 2. Acute syndrome that is due to presumed acute stroke, defined as FAST (Face, Arm, Speech, Time) scores of ≥2 with an arm motor deficit; 3. Time ≤3 hours from last seen well; 4. Systolic BP (SBP) ≥150mmHg. Exclusion Criteria: 1. Participants in coma (no response to tactile/verbal stimulation); or/and do not respond to "P" or "U" on the alert/verbal/painful/unresponsive (APVU) responsiveness scale; 2. Severe known co-morbid disease (e.g. cancer, chronic airflow disease, severe dementia, severe heart failure, pre-existing disability \[needing help\]); 3. Known history of epilepsy or seizure at onset; 4. Recent head injury (where there is potential for another type of intracranial haemorrhage or head trauma); 5. Hypoglycaemia (glucose\<4.0 mmol/L) as measured in the ambulance.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07231315 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Intracerebral Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07231315 currently recruiting?
Yes, NCT07231315 is actively recruiting participants. Contact the research team at canderson@georgeinstitute.org.au for enrollment information.
Where is the NCT07231315 trial being conducted?
This trial is being conducted at Sydney, Australia, Sydney, Australia, Sydney, Australia, Sydney, Australia and 2 additional locations.
Who is sponsoring the NCT07231315 clinical trial?
NCT07231315 is sponsored by The George Institute. The trial plans to enroll 163 participants.